GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
Ogilvy & Mather London developed the campaign, called Breathless Choir and set to Sting's "Every Breath You Take."
BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters
CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.
While it's made great strides, the healthcare industry is still behind in some technology and information safeguards.
Part of the challenge for drugmakers, medical-device makers and healthcare providers is finding the right digital talent and advocating for cultural changes within their organizations.
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.
The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.
The activity monitor dominates the fitness market, but competition in the overall health category is increasing.
- Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs
- When it comes to PCSK9s, payers resisted — and sales flopped
- Five things for pharma marketers to know: Thursday, January 12, 2017
- Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?
- Infographic: Can pharma give doctors what they want?
- Five things for pharma marketers to know: Tuesday, January 17, 2017
- Trump administration raises questions for rare-disease drugmakers
- If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold
- Five things for pharma marketers to know: Friday, January 13, 2017
- Klick Health's Elliot Langerman on the Power of Persuasion